Michael Adair

Patient-identified burden and unmet needs in patients with cluster headache: An evidence-based qualitative literature review

S. Reinsch, R. Casper, David Reeves, 2022, Cephalalgia Reports.

The motivation and energy inventory (MEI): Analysis of the clinically relevant response threshold in patients with major depressive disorder and emotional blunting using data from the COMPLETE study.

R. McIntyre, H. Loft, M. C. Christensen, 2022, Journal of affective disorders.

Predicting time to relapse in patients with schizophrenia according to patients’ relapse history: a historical cohort study using real-world data in Sweden

M. Bøg, L. Jönsson, K. T. Jørgensen, 2021, BMC Psychiatry.

Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer’s disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea

E. Cumbo, M. C. Christensen, Michael Adair, 2023, Frontiers in Aging Neuroscience.

Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study

M. C. Christensen, K. Simonsen, Michael Adair, 2022, Journal of psychopharmacology.

Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.

A. Fagiolini, H. Loft, I. Florea, 2023, Journal of affective disorders.

Clinical benefits of vortioxetine 20 mg/day in patients with major depressive disorder

A. Fagiolini, R. McIntyre, H. Loft, 2023, CNS Spectrums.